Slideshows Images Quizzes

Actos

Last reviewed on RxList: 1/11/2018
Actos Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 1/11/2018

Actos (pioglitazone hydrochloride) is a thiazolidinedione and increases the body's sensitivity to insulin. Actos is used for type 2 diabetes, not type 1 diabetes or diabetic ketoacidosis. Generic Actos is not available in the U.S., but is available in other countries as pioglitazone. Common side effects of Actos may include:

  • cold or flu-like symptoms (such as stuffy nose, sneezing, cough, sore throat),
  • headache,
  • gradual weight gain,
  • muscle pain,
  • back pain,
  • tooth problems, and
  • mouth pain.
  •  

    Tell your doctor if you have serious side effects of Actos including:

  • nausea,
  • vomiting,
  • stomach pain,
  • blood in the urine,
  • dark urine,
  • painful urination,
  • urinating more than usual,
  • shortness of breath, even with mild exertion,
  • swelling or rapid weight gain,
  • chest pain,
  • feeling unwell (malaise),
  • nausea,
  • upper stomach pain,
  • itching,
  • loss of appetite,
  • clay-colored stools,
  • blurred vision,
  • increased thirst or hunger,
  • pale skin,
  • easy bruising or bleeding,
  • weakness,
  • yellowing skin or eyes (jaundice), and
  • vision changes or loss.
  • Actos is available as tablets in strengths of 15, 30 or 45 mg. Dose is dependent on patient response and the prescribing doctor's clinical judgment; glucose tests may help determine doses. Actos and other similar drugs may exacerbate symptoms of congestive heart failure (dyspnea, edema, weight gain) and these symptoms may be serious. Patients with congestive heart failure classified as III or IV (NY Heart Association) should not take this Actos. Other serious side effects of Actos include nausea, vomiting, jaundice, and vision changes or loss; it may also cause hypoglycemia. There are no good studies in pregnant or breastfeeding women. Use of Actos in these patients should weigh risks versus benefits. There are no studies of safety or effectiveness of Actos on pediatric (under 18 years old) patients.

    Our Actos Drug Center provides a comprehensive view of available drug information as well as related drugs, user reviews, supplements, and diseases, and conditions.

    This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Actos Consumer Information

    Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Stop using pioglitazone and call your doctor at once if you have symptoms of liver damage: nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).

    Call your doctor at once if you have:

    • shortness of breath (even with mild exertion), swelling, rapid weight gain;
    • pink or red urine, painful or difficult urination, new or worsening urge to urinate;
    • changes in your vision; or
    • sudden unusual pain in your hand, arm, or foot.

    Common side effects may include:

    • headache;
    • muscle pain; or
    • cold symptoms such as stuffy nose, sinus pain, sneezing, sore throat.

    This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Read the entire detailed patient monograph for Actos (Pioglitazone Hydrochloride)

    Actos Professional Information

    SIDE EFFECTS

    The following serious adverse reactions are discussed elsewhere in the labeling:

    Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Over 8500 patients with type 2 diabetes have been treated with ACTOS in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetes and macrovascular disease treated with ACTOS in the PROactive clinical trial. In these trials, over 6000 patients have been treated with ACTOS for six months or longer, over 4500 patients have been treated with ACTOS for one year or longer, and over 3000 patients have been treated with ACTOS for at least two years.

    In six pooled 16-to 26-week placebo-controlled monotherapy and 16-to 24-week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with ACTOS and 5.8% for comparator-treated patients. The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with ACTOS than with placebo (3.0%).

    In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with ACTOS and 7.7% for placebo-treated patients. Congestive heart failure was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with ACTOS and 0.6% of patients treated with placebo.

    Common Adverse Events: 16-To 26-Week Monotherapy Trials

    A summary of the incidence and type of common adverse events reported in three pooled 16to 26-week placebo-controlled monotherapy trials of ACTOS is provided in Table 1. Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with ACTOS than in patients who received placebo. None of these adverse events were related to ACTOS dose.

    Table 1. Three Pooled 16-to 26-Week Placebo-Controlled Clinical Trials of ACTOS Monotherapy: Adverse Events Reported at an Incidence >5% and More Commonly in Patients Treated with ACTOS than in Patients Treated with Placebo

    % of Patients
      Placebo
    N=259
    ACTOS
    N=606
    Upper Respiratory Tract Infection 8.5 13.2
    Headache 6.9 9.1
    Sinusitis 4.6 6.3
    Myalgia 2.7 5.4
    Pharyngitis 0.8 5.1

    Common Adverse Events: 16-To 24-Week Add-On Combination Therapy Trials

    A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to sulfonylurea is provided in Table 2. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.

    Table 2. 16-to 24-Week Clinical Trials of ACTOS Add-on to Sulfonylurea

      16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Sulfonylurea than in Patients Treated with Placebo + Sulfonylurea
    % of Patients
    Placebo + Sulfonylurea
    N=187
    ACTOS 15 mg + Sulfonylurea
    N=184
    ACTOS 30 mg + Sulfonylurea
    N=189
    Edema 2.1 1.6 12.7
    Headache 3.7 4.3 5.3
    Flatulence 0.5 2.7 6.3
    Weight Increased 0 2.7 5.3
      24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Sulfonylurea than in Patients Treated with ACTOS 30 mg + Sulfonylurea
    % of Patients
    ACTOS 30 mg + Sulfonylurea
    N=351
    ACTOS 45 mg + Sulfonylurea
    N=351
    Hypoglycemia 13.4 15.7
    Edema 10.5 23.1
    Upper Respiratory Tract Infection 12.3 14.8
    Weight Increased 9.1 13.4
    Urinary Tract Infection 5.7 6.8
    Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of “edema.”

    A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to metformin is provided in Table 3. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.

    Table 3. 16-to 24-Week Clinical Trials of ACTOS Add-on to Metformin

      16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS + Metformin than in Patients Treated with Placebo + Metformin
    % of Patients
    Placebo + Metformin
    N=160
    ACTOS 30 mg + Metformin
    N=168
    Edema 2.5 6.0
    Headache 1.9 6.0
      24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Metformin than in Patients Treated with ACTOS 30 mg + Metformin
    % of Patients
    ACTOS 30 mg + Metformin
    N=411
    ACTOS 45 mg + Metformin
    N=416
    Upper Respiratory Tract Infection 12.4 13.5
    Edema 5.8 13.9
    Headache 5.4 5.8
    Weight Increased 2.9 6.7
    Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of “edema.”

    Table 4 summarizes the incidence and types of common adverse events reported in trials of ACTOS add-on to insulin. Terms that are reported represent those that occurred at an incidence of >5% and more commonly with the highest tested dose of ACTOS.

    Table 4. 16-to 24-Week Clinical Trials of ACTOS Add-on to Insulin

      16-Week Placebo-Controlled Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Insulin than in Patients Treated with Placebo + Insulin
    % of Patients
    Placebo + Insulin
    N=187
    ACTOS 15 mg + Insulin
    N=191
    ACTOS 30 mg + Insulin
    N=188
    Hypoglycemia 4.8 7.9 15.4
    Edema 7.0 12.6 17.6
    Upper Respiratory Tract Infection 9.6 8.4 14.9
    Headache 3.2 3.1 6.9
    Weight Increased 0.5 5.2 6.4
    Back Pain 4.3 2.1 5.3
    Dizziness 3.7 2.6 5.3
    Flatulence 1.6 3.7 5.3
      24-Week Non-Controlled Double-Blind Trial Adverse Events Reported in >5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Insulin than in Patients Treated with ACTOS 30 mg + Insulin
    % of Patients
    ACTOS 30 mg + Insulin
    N=345
    ACTOS 45 mg + Insulin
    N=345
    Hypoglycemia 43.5 47.8
    Edema 22.0 26.1
    Weight Increased 7.2 13.9
    Urinary Tract Infection 4.9 8.7
    Diarrhea 5.5 5.8
    Back Pain 3.8 6.4
    Blood Creatine Phosphokinase Increased 4.6 5.5
    Sinusitis 4.6 5.5
    Hypertension 4.1 5.5
    Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of “edema.”

    A summary of the overall incidence and types of common adverse events reported in the PROactive trial is provided in Table 5. Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with ACTOS than in patients who received placebo.

    Table 5. PROactive Trial: Incidence and Types of Adverse Events Reported in >5% of Patients Treated with ACTOS and More Commonly than Placebo

      % of Patients
    Placebo
    N=2633
    ACTOS
    N=2605
    Hypoglycemia 18.8 27.3
    Edema 15.3 26.7
    Cardiac Failure 6.1 8.1
    Pain in Extremity 5.7 6.4
    Back Pain 5.1 5.5
    Chest Pain 5.0 5.1
    Mean duration of patient follow-up was 34.5 months.

    Congestive Heart Failure

    A summary of the incidence of adverse events related to congestive heart failure is provided in Table 6 for the 16-to 24-week add-on to sulfonylurea trials, for the 16-to 24-week add-on to insulin trials, and for the 16-to 24-week add-on to metformin trials. None of the events were fatal.

    Table 6. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF)

    Patients Treated with ACTOS or Placebo Added on to a Sulfonylurea
      Number (%) of Patients
    Placebo-Controlled Trial
    (16 weeks)
    Non-Controlled Double-Blind Trial
    (24 weeks)
    Placebo + Sulfonylurea
    N=187
    ACTOS 15 mg + Sulfonylurea
    N=184
    ACTOS 30 mg + Sulfonylurea
    N=189
    ACTOS 30 mg + Sulfonylurea
    N=351
    ACTOS 45 mg + Sulfonylurea
    N=351
    At least one congestive heart failure event 2 (1.1%) 0 0 1 (0.3%) 6 (1.7%)
    Hospitalized 2 (1.1%) 0 0 0 2 (0.6%)
    Patients Treated with ACTOS or Placebo Added on to Insulin
      Number (%) of Patients
    Placebo-Controlled Trial (16 weeks) Non-Controlled Double-Blind Trial (24 weeks)
    Placebo + Insulin
    N=187
    ACTOS 15 mg + Insulin
    N=191
    ACTOS 30 mg + Insulin
    N=188
    ACTOS 30 mg + Insulin
    N=345
    ACTOS 45 mg + Insulin
    N=345
    At least one congestive heart failure event 0 2 (1.0%) 2 (1.1%) 3 (0.9%) 5 (1.4%)
    Hospitalized 0 2 (1.0%) 1 (0.5%) 1 (0.3%) 3 (0.9%)
    Patients Treated with ACTOS or Placebo Added on to Metformin
      Number (%) of Patients
    Placebo-Controlled Trial (16 weeks) Non-Controlled Double-Blind Trial (24 weeks)
    Placebo + Metformin
    N=160
    ACTOS 30 mg + Metformin
    N=168
    ACTOS 30 mg + Metformin
    N=411
    ACTOS 45 mg + Metformin
    N=416
    At least one congestive heart failure event 0 1 (0.6%) 0 1 (0.2%)
    Hospitalized 0 1 (0.6%) 0 1 (0.2%)

    Patients with type 2 diabetes and NYHA class II or early class III congestive heart failure were randomized to receive 24 weeks of double-blind treatment with either ACTOS at daily doses of 30 mg to 45 mg (n=262) or glyburide at daily doses of 10 mg to 15 mg (n=256). A summary of the incidence of adverse events related to congestive heart failure reported in this study is provided in Table 7.

    Table 7. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in Patients with NYHA Class II or III Congestive Heart Failure Treated with ACTOS or Glyburide

      Number (%) of Subjects
    ACTOS
    N=262
    Glyburide
    N=256
    Death due to cardiovascular causes (adjudicated) 5 (1.9%) 6 (2.3%)
    Overnight hospitalization for worsening CHF (adjudicated) 26 (9.9%) 12 (4.7%)
    Emergency room visit for CHF (adjudicated) 4 (1.5%) 3 (1.2%)
    Patients experiencing CHF progression during study 35 (13.4%) 21 (8.2%)

    Congestive heart failure events leading to hospitalization that occurred during the PROactive trial are summarized in Table 8.

    Table 8. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in PROactive Trial

      Number (%) of Patients
    Placebo
    N=2633
    ACTOS
    N=2605
    At least one hospitalized congestive heart failure event 108 (4.1%) 149 (5.7%)
    Fatal 22 (0.8%) 25 (1.0%)
    Hospitalized, nonfatal 86 (3.3%) 124 (4.7%)

    Cardiovascular Safety

    In the PROactive trial, 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to ACTOS (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins and fibrates). At baseline, patients had a mean age of 62 years, mean duration of diabetes of 9.5 years, and mean HbA1c of 8.1%. Mean duration of follow-up was 34.5 months. The primary objective of this trial was to examine the effect of ACTOS on mortality and macrovascular morbidity in patients with type 2 diabetes mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal myocardial infarction (MI) including silent MI, stroke, acute coronary syndrome, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle, and bypass surgery or revascularization in the leg. A total of 514 (19.7%) patients treated with ACTOS and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (hazard ratio 0.90; 95% Confidence Interval: 0.80, 1.02; p=0.10).

    Although there was no statistically significant difference between ACTOS and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with ACTOS. The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in Table 9.

    Table 9. PROactive: Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint

    Cardiovascular Events Placebo
    N=2633
    ACTOS
    N=2605
    First Events
    n (%)
    Total events
    n
    First Events
    n (%)
    Total events
    n
    Any event 572 (21.7) 900 514 (19.7) 803
      All-cause mortality 122 (4.6) 186 110 (4.2) 177
      Nonfatal myocardial infarction (MI) 118 (4.5) 157 105 (4.0) 131
      Stroke 96 (3.6) 119 76 (2.9) 92
      Acute coronary syndrome 63 (2.4) 78 42 (1.6) 65
      Cardiac intervention (CABG/PCI) 101 (3.8) 240 101 (3.9) 195
      Major leg amputation 15 (0.6) 28 9 (0.3) 28
      Leg revascularization 57 (2.2) 92 71 (2.7) 115
    CABG = coronary artery bypass grafting; PCI = percutaneous intervention

    Weight Gain

    Dose-related weight gain occurs when ACTOS is used alone or in combination with other antidiabetic medications. The mechanism of weight gain is unclear but probably involves a combination of fluid retention and fat accumulation.

    Tables 10 and 11 summarize the changes in body weight with ACTOS and placebo in the 16to 26-week randomized, double-blind monotherapy and 16-to 24-week combination add-on therapy trials and in the PROactive trial.

    Table 10. Weight Changes (kg) from Baseline During Randomized, Double-Blind Clinical Trials

      Control Group
    (Placebo)
    ACTOS
    15 mg
    ACTOS
    30 mg
    ACTOS
    45 mg
    Median
    (25th/75th percentile)
    Median
    (25th/75th percentile)
    Median
    (25th/75th percentile)
    Median
    (25th/75th percentile)
    Monotherapy
    (16 to 26 weeks)
      -1.4 (-2.7/0.0)
    N=256
    0.9 (-0.5/3.4)
    N=79
    1.0 (-0.9/3.4)
    N=188
    2.6 (0.2/5.4)
    N=79
    Combination Therapy
    (16 to 24 weeks)
    Sulfonylurea -0.5 (-1.8/0.7)
    N=187
    2.0 (0.2/3.2)
    N=183
    3.1 (1.1/5.4)
    N=528
    4.1 (1.8/7.3)
    N=333
    Metformin -1.4 (-3.2/0.3)
    N=160
    N/A 0.9 (-1.3/3.2)
    N=567
    1.8 (-0.9/5.0)
    N=407
    Insulin 0.2 (-1.4/1.4)
    N=182
    2.3 (0.5/4.3)
    N=190
    3.3 (0.9/6.3)
    N=522
    4.1 (1.4/6.8)
    N=338

    Table 11. Median Change in Body Weight in Patients Treated with ACTOS Versus Patients Treated with Placebo During the Double-Blind Treatment Period in the PROactive Trial

      Placebo ACTOS
    Median
    (25th/75th percentile)
    Median
    (25th/75th percentile)
    Change from baseline to final visit (kg) -0.5 (-3.3, 2.0)
    N=2581
    +3.6 (0.0, 7.5)
    N=2560
    Note: Median exposure for both ACTOS and Placebo was 2.7 years.

    Edema

    Edema induced from taking ACTOS is reversible when ACTOS is discontinued. The edema usually does not require hospitalization unless there is coexisting congestive heart failure. A summary of the frequency and types of edema adverse events occurring in clinical investigations of ACTOS is provided in Table 12.

    Table 12. Adverse Events of Edema in Patients Treated with ACTOS

      Number (%) of Patients
    Placebo ACTOS
    15 mg
    ACTOS
    30 mg
    ACTOS
    45 mg
    Monotherapy (16 to 26 weeks) 3 (1.2%)
    N=259
    2 (2.5%)
    N= 81
    13 (4.7%)
    N= 275
    11 (6.5%)
    N=169
    Combined Therapy
    (16 to 24 weeks)
    Sulfonylurea 4 (2.1%)
    N=187
    3 (1.6%)
    N=184
    61 (11.3%)
    N=540
    81 (23.1%)
    N=351
    Metformin 4 (2.5%)
    N=160
    N/A 34 (5.9%)
    N=579
    58 (13.9%)
    N=416
    Insulin 13 (7.0%)
    N=187
    24 (12.6%)
    N=191
    109 (20.5%)
    N=533
    90 (26.1%)
    N=345
    Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of “edema.”

    Table 13. Adverse Events of Edema in Patients in the PROactive Trial

    Number (%) of Patients
    Placebo
    N=2633
    ACTOS
    N=2605
    419 (15.9%) 712 (27.3%)
    Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of “edema.”

    Hepatic Effects

    There has been no evidence of induced hepatotoxicity with ACTOS in the ACTOS controlled clinical trial database to date. One randomized, double-blind 3-year trial comparing ACTOS to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter. A total of 3/1051 (0.3%) patients treated with ACTOS and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with ACTOS in the ACTOS controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced liver injury.

    Hypoglycemia

    In the ACTOS clinical trials, adverse events of hypoglycemia were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing.

    In the 16-week add-on to sulfonylurea trial, the incidence of reported hypoglycemia was 3.7% with ACTOS 30 mg and 0.5% with placebo. In the 16-week add-on to insulin trial, the incidence of reported hypoglycemia was 7.9% with ACTOS 15 mg, 15.4% with ACTOS 30 mg, and 4.8% with placebo.

    The incidence of reported hypoglycemia was higher with ACTOS 45 mg compared to ACTOS 30 mg in both the 24-week add-on to sulfonylurea trial (15.7% vs. 13.4%) and in the 24-week add-on to insulin trial (47.8% vs. 43.5%).

    Three patients in these four trials were hospitalized due to hypoglycemia. All three patients were receiving ACTOS 30 mg (0.9%) in the 24-week add-on to insulin trial. An additional 14 patients reported severe hypoglycemia (defined as causing considerable interference with patient’s usual activities) that did not require hospitalization. These patients were receiving ACTOS 45 mg in combination with sulfonylurea (n=2) or ACTOS 30 mg or 45 mg in combination with insulin (n=12).

    Urinary Bladder Tumors

    Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [see Nonclinical Toxicology]. During the three year PROactive clinical trial, 14 patients out of 2605 (0.54%) randomized to ACTOS and 5 out of 2633 (0.19%) randomized to placebo were diagnosed with bladder cancer. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 6 (0.23%) cases on ACTOS and two (0.08%) cases on placebo. After completion of the trial, a large subset of patients was observed for up to 10 additional years, with little additional exposure to ACTOS. During the 13 years of both PROactive and observational follow-up, the occurrence of bladder cancer did not differ between patients randomized to ACTOS or placebo (HR =1.00; 95% CI: 0.59-1.72) [see WARNINGS AND PRECAUTIONS].

    Laboratory Abnormalities

    Hematologic Effects

    ACTOS may cause decreases in hemoglobin and hematocrit. In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with ACTOS compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first 4 to 12 weeks of therapy and remained relatively constant thereafter. These changes may be related to increased plasma volume associated with ACTOS therapy and are not likely to be associated with any clinically significant hematologic effects.

    Creatine Phosphokinase

    During protocol-specified measurement of serum creatine phosphokinase (CPK) in ACTOS clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with ACTOS (values of 2150 to 11400 IU/L) and in no comparator-treated patients. Six of these nine patients continued to receive ACTOS, two patients were noted to have the CPK elevation on the last day of dosing and one patient discontinued ACTOS due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to ACTOS therapy is unknown.

    Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of ACTOS. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Postmarketing reports of congestive heart failure have been reported in patients treated with ACTOS, both with and without previously known heart disease and both with and without concomitant insulin administration.

    In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure [see BOX WARNING and WARNINGS AND PRECAUTIONS].

    Read the entire FDA prescribing information for Actos (Pioglitazone Hydrochloride)

    CONTINUE SCROLLING FOR RELATED ARTICLE

    Health Solutions From Our Sponsors